Hematopoietic stem cell transplant as a platform for tumor immunotherapy

被引：0
作者：
Fuchs, EJ [1 ]
Whartenby, KA [1 ]
机构：
[1] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Dept Oncol, Div Immunol & Hematopoiesis, Baltimore, MD 21231 USA
来源：
CURRENT OPINION IN MOLECULAR THERAPEUTICS | 2004年 / 6卷 / 01期
关键词：
blood or marrow transplant; donor lymphocyte infusion; gene therapy; immunotherapy; tumor vaccine;
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Blood or marrow transplantation (BMT) has been utilized as a cancer therapy with varying levels of success. While it has been an important option for many hematological malignancies, it has met with less success in solid tumors. More recently, new combinations of therapies with BMT have been developed to enhance the efficacy of this therapy and to expand the number of target tumors. This review highlights current uses of BMT, rationales for experimental approaches using BMT alone or as a part of a combination therapy, and reviews some of the novel therapies that have been developed in tumor immunotherapy with BMT, in addition to the implications for translation.
引用
收藏
页码：48 / 53
页数：6
相关论文
共 53 条
[41]   Immunotherapy using heat-shock protein preparations of leukemia cells after syngeneic bone marrow transplantation in mice [J].
Sato, K ;
Torimoto, Y ;
Tamura, Y ;
Shindo, M ;
Shinzaki, H ;
Hirai, K ;
Kohgo, Y .
BLOOD, 2001, 98 (06) :1852-1857
[42]   Donor T cell-derived TNF is required for graft-versus-host disease and graft-versus-tumor activity after bone marrow transplantation [J].
Schmaltz, C ;
Alpdogan, O ;
Muriglan, SJ ;
Kappel, BJ ;
Rotolo, JA ;
Ricchetti, ET ;
Greenberg, AS ;
Willis, LM ;
Murphy, GF ;
Crawford, JM ;
van den Brink, MRM .
BLOOD, 2003, 101 (06) :2440-2445
[43]   T cells require TRAIL for optimal graft-versus-tumor activity [J].
Schmaltz, C ;
Alpdogan, O ;
Kappel, BJ ;
Muriglan, SJ ;
Rotolo, JA ;
Ongchin, J ;
Willis, LM ;
Greenberg, AS ;
Eng, JM ;
Crawford, JM ;
Murphy, GF ;
Yagita, H ;
Walczak, H ;
Peschon, JJ ;
van den Brink, MRM .
NATURE MEDICINE, 2002, 8 (12) :1433-1437
[44]   Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases [J].
Slavin, S ;
Nagler, A ;
Naparstek, E ;
Kapelushnik, Y ;
Aker, M ;
Cividalli, G ;
Varadi, G ;
Kirschbaum, M ;
Ackerstein, A ;
Samuel, S ;
Amar, A ;
Brautbar, C ;
Ben-Tal, O ;
Eldor, A ;
Or, R .
BLOOD, 1998, 91 (03) :756-763
[45]   Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression [J].
Sotomayor, EM ;
Borrello, I ;
Rattis, FM ;
Cuenca, AG ;
Abrams, J ;
Staveley-O'Carroll, K ;
Levitsky, HI .
BLOOD, 2001, 98 (04) :1070-1077
[46]   Antineoplastic effects of partially HLA-Matched irradiated blood mononuclear cells in patients with renal cell carcinoma [J].
Strair, RK ;
Schaar, D ;
Medina, D ;
Todd, MB ;
Aisner, J ;
DiPaola, RS ;
Manago, J ;
Knox, B ;
Jenkison, A ;
Senzon, R ;
Baker, C ;
Dudek, L ;
Ciardella, M ;
Kuriyan, M ;
Rubin, A ;
Lattime, EC .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (20) :3785-3791
[47]  
Teshima T, 2002, CANCER RES, V62, P796
[48]   Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors [J].
Ueno, NT ;
Cheng, YC ;
Rondón, G ;
Tannir, NM ;
Gajewski, JL ;
Couriel, DR ;
Hosing, C ;
de Lima, MJ ;
Anderlini, P ;
Khouri, IF ;
Booser, DJ ;
Hortobagyi, GN ;
Pagliaro, LC ;
Jonasch, E ;
Giralt, SA ;
Champlin, RE .
BLOOD, 2003, 102 (10) :3829-3836
[49]   New strategies in allogeneic stem cell transplantation: immunotherapy using irradiated allogeneic T cells [J].
Waller, EK ;
Boyer, M .
BONE MARROW TRANSPLANTATION, 2000, 25 (Suppl 2) :S20-S24
[50]  
Wang J, 2002, CANCER RES, V62, P208
123456